Magnesium bisglycinate is used to close a dietary gap without the laxative effect of oxide or citrate. One study showed a small insomnia benefit, larger with low magnesium. Blood-pressure and glucose findings come from other magnesium trials. Risks are loose stools at higher doses and high blood magnesium in advanced kidney disease. Interactions include thyroid hormone, antibiotics, and osteoporosis drugs. (Full Review)

Protocol

Sleep-oriented evening dose

200–250 mg elemental magnesium

30–60 minutes before bed; public protocols often use 200 mg; the sleep trial used 250 mg

Repletion versus food

310–420 mg/day from all sources

The chelate is used to close the gap, not to replace magnesium-rich food

Buffered versus fully reacted chelate

Fully reacted chelate

Fully reacted chelates differ from oxide blended with glycine; protocols specify bisglycinate chelate versus buffered labels

Time to effect

Blood pressure

4–12 weeks

Mixed-salt trials; small average drop with already-normal pressure

Sleep-score changes

4 weeks

Some movement earlier; larger with low dietary magnesium

Pregnancy-associated leg cramps

4 weeks

Positive bisglycinate trial; mixed-salt reviews conflict

Benefits

High: Lower Blood Pressure With Magnesium Repletion; Glucose Handling in Diabetes or High Risk; Fewer Migraine Attacks With Oral Magnesium

Medium: Modest Improvement in Insomnia Severity; Pregnancy-Associated Leg Cramps; Bone Mineral Density

Low: Gastrointestinal Tolerance Versus Oxide; Depressive Symptom Scores; Anxiety and Stress Scores

Speculative: DNA Repair and Longevity Biology; Vasomotor Relief; Brain Magnesium Beyond Sleep

Contraindications

Advanced chronic kidney disease or dialysis (eGFR below 30 mL/min/1.73 m²), unless a nephrology protocol is already using magnesium on purpose

Myasthenia gravis or other severe neuromuscular junction disease

Known hypersensitivity to the chelate or capsule excipients

Concurrent high-dose magnesium cathartics or antacids (large elemental loads)

Key Interactions

Tetracyclines and fluoroquinolones (doxycycline, ciprofloxacin); separate by at least 2 hours before or 4–6 hours after

Oral bisphosphonates (alendronate, risedronate); separate by several hours

Levothyroxine; hours apart, empty stomach

Blood-pressure drugs (amlodipine, lisinopril, hydrochlorothiazide); additive pressure lowering

Potassium-sparing diuretics and potassium supplements; combined electrolyte shifts

Proton-pump inhibitors (omeprazole, esomeprazole) and loop diuretics (furosemide); deplete magnesium

Calcium, zinc, and iron supplements; separate from high-dose mineral boluses

Other magnesium salts, antacids, and cathartics (oxide, citrate, hydroxide); additive elemental load

Glycine, GABA, and other evening calming supplements; overlapping sedation

Risk & Side Effects

High: Loose Stools and Gut Cramping at Higher Doses; Additive Blood-Pressure Lowering

Medium: High Blood Magnesium in Advanced Kidney Disease

Low: Reduced Absorption of Some Oral Drugs

Speculative: Excess Glycine Load; Neuromuscular Weakness Outside Kidney Failure

Monitoring

Marker	Target	Why
Serum magnesium	2.0–2.3 mg/dL (0.82–0.95 mmol/L)	Confirms frank deficit or excess
Red-cell magnesium	5.0–6.5 mg/dL	Tracks intracellular stores better than serum
eGFR (creatinine or cystatin C)	≥60 mL/min/1.73 m² for unsupervised oral repletion	Safety gate for accumulation
25-hydroxyvitamin D	40–60 ng/mL	Magnesium-dependent vitamin D handling
Blood pressure	<120/80 mm Hg if that is the target	Captures the mixed-salt pressure effect
Potassium	4.0–4.5 mmol/L	Shared wasting with diuretics

Cadence: 4 weeks after starting, then every 6–12 months if dose and kidney function are stable; earlier if diarrhea, light-headedness, or a drug change; tighter loop if eGFR under 60 mL/min/1.73 m² or other magnesium products added

Qualitative Assessment

Sleep latency and night awakenings over two to four weeks, not a single night
Stool form (formed stools, not a cathartic effect)
Muscle cramp frequency if that was the reason for use
Daytime energy and next-day grogginess
Light-headedness on standing after dose increases

Magnesium Bisglycinate for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment